These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 29962464)

  • 1. [Development of Enzyme Drugs Derived from Transgenic Silkworms to Treat Lysosomal Diseases].
    Itoh K; Nishioka SI; Hidaka T; Tsuji D; Maita N
    Yakugaku Zasshi; 2018; 138(7):885-893. PubMed ID: 29962464
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent progress in development of transgenic silkworms overexpressing recombinant human proteins with therapeutic potential in silk glands.
    Itoh K; Kobayashi I; Nishioka S; Sezutsu H; Machii H; Tamura T
    Drug Discov Ther; 2016 Feb; 10(1):34-9. PubMed ID: 26971553
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting macrophages with baculovirus-produced lysosomal enzymes: implications for enzyme replacement therapy of the glycoprotein storage disorder galactosialidosis.
    Bonten EJ; Wang D; Toy JN; Mann L; Mignardot A; Yogalingam G; D'Azzo A
    FASEB J; 2004 Jun; 18(9):971-3. PubMed ID: 15084520
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glyco-engineering strategies for the development of therapeutic enzymes with improved efficacy for the treatment of lysosomal storage diseases.
    Oh DB
    BMB Rep; 2015 Aug; 48(8):438-44. PubMed ID: 25999178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Short-term, high dose enzyme replacement therapy in sialidosis mice.
    Wang D; Bonten EJ; Yogalingam G; Mann L; d'Azzo A
    Mol Genet Metab; 2005 Jul; 85(3):181-9. PubMed ID: 15979029
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enzyme enhancement therapeutics for lysosomal storage diseases: Current status and perspective.
    Thomas R; Kermode AR
    Mol Genet Metab; 2019 Feb; 126(2):83-97. PubMed ID: 30528228
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elimination of abnormal sialylglycoproteins in fibroblasts with sialidosis and galactosialidosis by normal gene transfer and enzyme replacement.
    Oheda Y; Kotani M; Murata M; Sakuraba H; Kadota Y; Tatano Y; Kuwahara J; Itoh K
    Glycobiology; 2006 Apr; 16(4):271-80. PubMed ID: 16361247
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nanotechnology-based approaches for treating lysosomal storage disorders, a focus on Fabry disease.
    Abasolo I; Seras-Franzoso J; Moltó-Abad M; Díaz-Riascos V; Corchero JL; Pintos-Morell G; Schwartz S
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2021 May; 13(3):e1684. PubMed ID: 33314628
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lysosomal enzyme replacement therapies: Historical development, clinical outcomes, and future perspectives.
    Solomon M; Muro S
    Adv Drug Deliv Rev; 2017 Sep; 118():109-134. PubMed ID: 28502768
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lysosomal metabolism of glycoproteins.
    Winchester B
    Glycobiology; 2005 Jun; 15(6):1R-15R. PubMed ID: 15647514
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enzyme replacement therapy for lysosomal storage diseases.
    Ohashi T
    Pediatr Endocrinol Rev; 2012 Oct; 10 Suppl 1():26-34. PubMed ID: 23330243
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enzyme replacement therapy for lysosomal storage diseases.
    Lachmann RH
    Curr Opin Pediatr; 2011 Dec; 23(6):588-93. PubMed ID: 21946346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Galactosialidosis: preclinical enzyme replacement therapy in a mouse model of the disease, a proof of concept.
    Cadaoas J; Hu H; Boyle G; Gomero E; Mosca R; Jayashankar K; Machado M; Cullen S; Guzman B; van de Vlekkert D; Annunziata I; Vellard M; Kakkis E; Koppaka V; d'Azzo A
    Mol Ther Methods Clin Dev; 2021 Mar; 20():191-203. PubMed ID: 33426146
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New strategies for enzyme replacement therapy for lysosomal storage diseases.
    Grubb JH; Vogler C; Sly WS
    Rejuvenation Res; 2010; 13(2-3):229-36. PubMed ID: 20345279
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current treatment options and novel nanotechnology-driven enzyme replacement strategies for lysosomal storage disorders.
    Del Grosso A; Parlanti G; Mezzena R; Cecchini M
    Adv Drug Deliv Rev; 2022 Sep; 188():114464. PubMed ID: 35878795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular mechanisms of pathogenesis in a glycosphingolipid and a glycoprotein storage disease.
    d'Azzo A; Bonten E
    Biochem Soc Trans; 2010 Dec; 38(6):1453-7. PubMed ID: 21118106
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emptying the stores: lysosomal diseases and therapeutic strategies.
    Platt FM
    Nat Rev Drug Discov; 2018 Feb; 17(2):133-150. PubMed ID: 29147032
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiac involvement in Lysosomal Storage Diseases.
    Sestito S; Parisi F; Tallarico V; Tarsitano F; Roppa K; Pensabene L; Chimenz R; Ceravolo G; Calabrò MP; De Sarro R; Moricca MT; Bonapace G; Concolino D
    J Biol Regul Homeost Agents; 2020; 34(4 Suppl. 2):107-119. SPECIAL ISSUE: FOCUS ON PEDIATRIC CARDIOLOGY. PubMed ID: 33000609
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enzyme Replacement Therapy: A Review and Its Role in Treating Lysosomal Storage Diseases.
    Li M
    Pediatr Ann; 2018 May; 47(5):e191-e197. PubMed ID: 29750286
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transgenic silkworms that weave recombinant proteins into silk cocoons.
    Tomita M
    Biotechnol Lett; 2011 Apr; 33(4):645-54. PubMed ID: 21184136
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.